뇌졸중 치료 시장 : 전략적 인사이트와 예측(2026-2035년)

The Global Stroke Treatment Landscape Report is projected to grow at a CAGR of 7.9% during the forecast period, increasing from USD 34.94 billion in 2026 to USD 69.06 billion by 2035.

Stroke is one of the leading causes of death and long-term disability worldwide, requiring rapid diagnosis and timely intervention to minimize neurological damage. The treatment landscape includes thrombolytic drugs, antiplatelet agents, anticoagulants, endovascular therapies, surgical procedures, rehabilitation services, and emerging regenerative approaches. Continuous advances in artificial intelligence-assisted imaging, precision medicine, and neurovascular interventions are improving treatment outcomes while creating new opportunities for pharmaceutical companies, biotechnology firms, and medical device manufacturers.

Market Drivers

Increasing Global Stroke Burden

The growing prevalence of hypertension, diabetes, obesity, atrial fibrillation, and aging populations continues to increase the incidence of stroke worldwide. Rising patient volumes are driving demand for both acute intervention and long-term rehabilitation services.

Expansion of Mechanical Thrombectomy

Mechanical thrombectomy has become a cornerstone of acute ischemic stroke management. Healthcare systems are expanding stroke center networks and neurointerventional capabilities, increasing demand for complementary pharmacological therapies and advanced treatment technologies.

Growing Focus on Functional Recovery

Healthcare providers are increasingly emphasizing long-term neurological recovery rather than survival alone. This has accelerated development of neuroprotective agents, regenerative medicine, rehabilitation technologies, and personalized treatment strategies that improve functional independence.

Advancements in Stroke Imaging

Rapid adoption of CT perfusion, MRI, artificial intelligence-assisted imaging, and imaging-guided treatment pathways enables faster diagnosis and better patient selection, improving clinical outcomes and expanding eligibility for advanced stroke interventions.

Market Restraints

Limited Therapeutic Window

Acute stroke therapies remain highly time-dependent. Delayed patient presentation continues to limit eligibility for thrombolysis and endovascular intervention, reducing the proportion of patients who can benefit from advanced treatment.

High Infrastructure Requirements

Comprehensive stroke care requires specialized neurointerventional teams, advanced imaging equipment, intensive care facilities, and coordinated emergency response systems, limiting access in many developing regions.

Challenges in Neuroprotective Drug Development

Despite extensive research, many neuroprotective drug candidates have experienced limited clinical success because of the complex pathophysiology of stroke and heterogeneous patient populations.

Treatment and Technology Insights

The global stroke treatment market can be segmented by drug type, stroke type, treatment type, route of administration, end user, and geography.

By drug type, the market includes thrombolytics, antiplatelet agents, anticoagulants, and other supportive therapies. Thrombolytic agents remain essential for acute ischemic stroke treatment, while antiplatelet and anticoagulant therapies play a critical role in secondary stroke prevention.

By stroke type, the market comprises ischemic stroke, hemorrhagic stroke, transient ischemic attack (TIA), and other cerebrovascular disorders. Ischemic stroke accounts for the largest share of treatment demand because it represents the majority of stroke cases globally.

By treatment type, the market includes IV medication, endovascular therapy, and surgical procedures, including mechanical thrombectomy and carotid endarterectomy (CEA). Endovascular therapy continues to be one of the fastest-growing segments as clinical evidence supports improved outcomes in appropriately selected patients.

By route of administration, treatments include oral, intravenous, and other administration routes. Intravenous therapies remain the standard for acute intervention, while oral medications dominate secondary prevention.

By end user, the market includes hospitals, specialty neurology centers, rehabilitation centers, and other healthcare facilities. Comprehensive stroke centers continue to lead adoption of advanced imaging, thrombectomy, and multidisciplinary stroke management.

Technological advances including artificial intelligence-assisted imaging, precision diagnostics, biomarker-guided treatment selection, digital health platforms, wearable monitoring technologies, and regenerative medicine continue to improve diagnosis, treatment selection, and long-term neurological recovery.

Market Trends

The stroke treatment landscape continues to evolve toward personalized and technology-driven care.

Key trends include:

• Expansion of mechanical thrombectomy utilization.
• Increasing investment in neuroprotective therapies.
• Growing development of regenerative medicine.
• Wider adoption of artificial intelligence-assisted imaging.
• Expansion of comprehensive stroke center networks.
• Greater emphasis on post-stroke rehabilitation and recovery.
• Increasing use of precision medicine and biomarker-guided treatment strategies.

Regional Insights

North America remains the largest stroke treatment market because of advanced healthcare infrastructure, widespread adoption of comprehensive stroke centers, favorable reimbursement systems, and extensive investment in neurological innovation. The region continues to lead adoption of advanced imaging technologies, thrombectomy, and emerging therapies.

Europe maintains a strong market position through structured stroke care pathways, established national healthcare systems, and ongoing investment in evidence-based treatment approaches. Collaborative research and standardized clinical guidelines continue to support market growth.

Asia-Pacific is expected to register the fastest growth owing to increasing stroke incidence, expanding healthcare infrastructure, improving access to specialized stroke care, and rising healthcare investment across China, Japan, India, South Korea, and Australia.

Latin America and the Middle East & Africa continue to strengthen stroke care through healthcare modernization, improved diagnostic capabilities, and expanding access to specialized neurological services.

Competitive Landscape

The global stroke treatment market consists of multinational pharmaceutical companies, biotechnology firms, neurovascular device manufacturers, diagnostic imaging companies, and digital health providers.

Organizations continue investing in thrombolytic therapies, neuroprotective drugs, regenerative medicine, mechanical thrombectomy technologies, artificial intelligence-assisted diagnostics, and precision medicine. Strategic collaborations, licensing agreements, mergers and acquisitions, and clinical research partnerships remain key strategies for strengthening market position and accelerating commercialization.

Future Outlook

The future of the stroke treatment market will be driven by advances in precision neurology, regenerative medicine, artificial intelligence, digital health, and minimally invasive neurovascular technologies. Continued innovation in neuroprotection, imaging-guided intervention, biomarker-guided therapy selection, and rehabilitation technologies is expected to improve clinical outcomes while expanding commercial opportunities.

Greater integration of real-world evidence, adaptive clinical trials, and personalized treatment strategies is expected to accelerate innovation and strengthen the global stroke treatment landscape through 2035.

Conclusion

The global Stroke Treatment Market is expected to demonstrate strong growth through 2035, supported by increasing stroke prevalence, expanding use of mechanical thrombectomy, advances in imaging technologies, and continued innovation in neuroprotective and regenerative therapies. Although challenges related to treatment timing, infrastructure requirements, and complex neurological recovery remain, ongoing advances in precision medicine, artificial intelligence, and multidisciplinary stroke care are expected to significantly improve patient outcomes while creating attractive opportunities for pharmaceutical companies, biotechnology firms, medical device manufacturers, healthcare providers, and investors.

Key Benefits of this Report

• Comprehensive analysis of the global stroke treatment market and future growth opportunities.
• Detailed evaluation of treatment modalities, therapeutic innovations, and market trends.
• Competitive assessment of leading companies, product portfolios, and strategic initiatives.
• Insights into regulatory developments, reimbursement trends, and commercialization opportunities.
• Valuable resource for pharmaceutical companies, biotechnology firms, medical device manufacturers, healthcare providers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Market forecasting, competitive intelligence, pipeline assessment, portfolio optimization, licensing and partnership evaluation, commercialization planning, regulatory strategy development, investment analysis, and identification of emerging business opportunities.

Report Coverage

• Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global stroke treatment market by drug type, stroke type, treatment type, route of administration, end user, and geography
• Evaluation of market size, growth drivers, restraints, treatment landscape, competitive dynamics, and emerging technology trends
• Assessment of regulatory developments, reimbursement landscape, strategic collaborations, licensing activities, mergers and acquisitions, and commercialization strategies
• Analysis of thrombolytics, antiplatelet agents, anticoagulants, endovascular therapies, mechanical thrombectomy, carotid endarterectomy, regenerative medicine, artificial intelligence-enabled stroke care, and future market opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Overview
• 1.2 Key Findings
• 1.3 Stroke Burden Snapshot
• 1.4 Current Treatment Paradigm
• 1.5 Major Market Trends
• 1.6 Competitive Highlights
• 1.7 Pipeline Outlook
• 1.8 Future Market Opportunities

2. Disease & Epidemiology Analysis

• 2.1 Stroke Disease Overview
  • 2.1.1 Definition and Clinical Background
  • 2.1.2 Disease Pathophysiology
  • 2.1.3 Risk Factors and Comorbidities
  • 2.1.4 Disease Burden and Healthcare Impact
• 2.2 Stroke Classification
  • 2.2.1 Ischemic Stroke
  • 2.2.2 Hemorrhagic Stroke
    • 2.2.2.1 Intracerebral Hemorrhage (ICH)
    • 2.2.2.2 Subarachnoid Hemorrhage (SAH)
  • 2.2.3 Transient Ischemic Attack (TIA)
• 2.3 Epidemiology Analysis
  • 2.3.1 Incident Cases
  • 2.3.2 Prevalent Cases
  • 2.3.3 Mortality Trends
  • 2.3.4 Disability-Adjusted Life Years (DALYs)
  • 2.3.5 Age-wise Distribution
  • 2.3.6 Gender-wise Distribution
  • 2.3.7 Stroke Recurrence Rates
• 2.4 Epidemiology by Stroke Type
  • 2.4.1 Ischemic Stroke Epidemiology
  • 2.4.2 Hemorrhagic Stroke Epidemiology
  • 2.4.3 TIA Epidemiology
• 2.5 Unmet Clinical Needs
  • 2.5.1 Early Diagnosis Challenges
  • 2.5.2 Treatment Window Limitations
  • 2.5.3 Access to Specialized Stroke Centers
  • 2.5.4 Long-Term Disability Management

3. Market Dynamics

• 3.1 Market Drivers
  • 3.1.1 Rising Global Stroke Incidence
  • 3.1.2 Aging Population
  • 3.1.3 Increasing Prevalence of Cardiovascular Risk Factors
  • 3.1.4 Growing Awareness of Early Intervention
  • 3.1.5 Expansion of Stroke Care Infrastructure
• 3.2 Market Restraints
  • 3.2.1 Narrow Therapeutic Time Window
  • 3.2.2 High Cost of Advanced Stroke Care
  • 3.2.3 Limited Access in Developing Regions
  • 3.2.4 Post-Stroke Rehabilitation Challenges
• 3.3 Market Opportunities
  • 3.3.1 Neuroprotection Therapies
  • 3.3.2 Advanced Reperfusion Strategies
  • 3.3.3 AI-Enabled Stroke Management
  • 3.3.4 Emerging Regenerative Medicine Approaches
• 3.4 Market Challenges
  • 3.4.1 Clinical Trial Complexity
  • 3.4.2 Reimbursement Variability
  • 3.4.3 Long-Term Outcome Assessment
• 3.5 Porter's Five Forces Analysis
• 3.6 PESTLE Analysis
• 3.7 Value Chain Analysis
• 3.8 Stakeholder Ecosystem Analysis

4. Commercial & Market Access

• 4.1 Market Access Overview
• 4.2 Reimbursement Landscape
• 4.3 Pricing Analysis
• 4.4 Healthcare Infrastructure Assessment
• 4.5 Treatment Accessibility Analysis
• 4.6 Public Health Initiatives
• 4.7 Patient Journey Assessment
  • 4.7.1 Symptom Recognition
  • 4.7.2 Emergency Care
  • 4.7.3 Acute Treatment
  • 4.7.4 Rehabilitation
  • 4.7.5 Secondary Prevention

5. Innovation & Pipeline Landscape

• 5.1 Pipeline Overview
• 5.2 Pipeline Distribution by Development Stage
  • 5.2.1 Discovery and Preclinical
  • 5.2.2 Phase I
  • 5.2.3 Phase II
  • 5.2.4 Phase III
• 5.3 Pipeline Analysis by Modality
  • 5.3.1 Small Molecules
  • 5.3.2 Biologics
  • 5.3.3 Cell Therapies
  • 5.3.4 Gene-Based Therapies
  • 5.3.5 Combination Therapies
• 5.4 Pipeline Analysis by Mechanism of Action
  • 5.4.1 Thrombolysis Enhancement
  • 5.4.2 Neuroprotection
  • 5.4.3 Anti-Inflammatory Mechanisms
  • 5.4.4 Vascular Repair and Regeneration
  • 5.4.5 Secondary Prevention Approaches
• 5.5 Clinical Trial Landscape
  • 5.5.1 Ongoing Trials by Phase
  • 5.5.2 Trials by Sponsor Type
  • 5.5.3 Trials by Stroke Subtype
  • 5.5.4 Geographic Distribution of Trials
• 5.6 Emerging Technologies
  • 5.6.1 AI-Assisted Stroke Management
  • 5.6.2 Digital Therapeutics
  • 5.6.3 Advanced Imaging Technologies
  • 5.6.4 Biomarker Development

6. Treatment Landscape

• 6.1 Current Treatment Algorithm
• 6.2 Acute Stroke Management
  • 6.2.1 Intravenous Thrombolysis
  • 6.2.2 Mechanical Thrombectomy
  • 6.2.3 Antithrombotic Therapy
  • 6.2.4 Blood Pressure Management
• 6.3 Secondary Prevention
  • 6.3.1 Antiplatelet Therapy
  • 6.3.2 Anticoagulation Therapy
  • 6.3.3 Lipid-Lowering Therapy
  • 6.3.4 Diabetes Management
  • 6.3.5 Hypertension Control
• 6.4 Rehabilitation Landscape
  • 6.4.1 Physical Rehabilitation
  • 6.4.2 Occupational Therapy
  • 6.4.3 Speech and Language Therapy
  • 6.4.4 Digital Rehabilitation Solutions
• 6.5 Treatment Guidelines Assessment
  • 6.5.1 American Guidelines
  • 6.5.2 European Guidelines
  • 6.5.3 Asian Clinical Practice Trends

7. Global Stroke Treatment Landscape Report Size & Forecast

• 7.1 Global Market Size Analysis (Historical)
• 7.2 Global Market Forecast
• 7.3 Market Forecast by Drug Type
• 7.4 Market Forecast by Stroke Type
• 7.5 Market Forecast by Route of Administration
• 7.6 Market Forecast by End User
• 7.7 Scenario Analysis
  • 7.8.1 Base Case
  • 7.8.2 Optimistic Case
  • 7.8.3 Conservative Case

8. Global Stroke Treatment Landscape Report Segmentation

• 8.1 By Drug Type
  • 8.1.1 Thrombolytics
  • 8.1.2 Antiplatelet Agents
  • 8.1.3 Anticoagulants
  • 8.1.4 Others
• 8.2 By Stroke Type
  • 8.2.1 Ischemic Stroke
    • 8.2.1.1. Thrombotic
    • 8.2.1.2. Embolic
  • 8.2.2 Hemorrhagic Stroke
  • 8.2.3 Transient Ischemic Attack
  • 8.2.4 Others
• 8.3 By Treatment Type
  • 8.3.1 IV Medication
  • 8.3.2 Endovascular Therapy
  • 8.3.3 Surgical Procedures
    • 8.3.3.1 Mechanical Thrombectomy
    • 8.3.3.2 Carotid Endarterectomy (CEA)
    • 8.3.3.3 Others
• 8.4 By Route of Administration
  • 8.4.1 Oral
  • 8.4.2 Intravenous
  • 8.4.3 Others
• 8.5 By End User
  • 8.5.1 Hospitals
  • 8.5.2 Specialty Neurology Centers
  • 8.5.3 Rehabilitation Centers
  • 8.5.4 Others

9. Geographical Analysis

• 9.1 North America
  • 9.1.1 Market Size and Forecast
  • 9.1.2 Epidemiology Overview
  • 9.1.3 Demand Drivers
  • 9.1.4 Regulatory Overview
  • 9.1.5 Reimbursement Environment
  • 9.1.6 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Market Size and Forecast
  • 9.2.2 Epidemiology Overview
  • 9.2.3 Demand Drivers
  • 9.2.4 Regulatory Overview
  • 9.2.5 Reimbursement Environment
  • 9.2.6 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Market Size and Forecast
  • 9.3.2 Epidemiology Overview
  • 9.3.3 Demand Drivers
  • 9.3.4 Regulatory Overview
  • 9.3.5 Reimbursement Environment
  • 9.3.6 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Market Size and Forecast
  • 9.4.2 Epidemiology Overview
  • 9.4.3 Demand Drivers
  • 9.4.4 Regulatory Overview
  • 9.4.5 Reimbursement Environment
  • 9.4.6 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Market Size and Forecast
  • 9.5.2 Epidemiology Overview
  • 9.5.3 Demand Drivers
  • 9.5.4 Regulatory Overview
  • 9.5.5 Reimbursement Environment
  • 9.5.6 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
  • 10.1.1 Market Size
  • 10.1.2 Epidemiology
  • 10.1.3 Regulatory Framework
  • 10.1.4 Reimbursement
  • 10.1.5 Key Companies and Product Presence
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 Global Regulatory Overview
• 11.2 United States (FDA)
  • 11.2.1 Drug Approval Pathways
  • 11.2.2 Expedited Programs
  • 11.2.3 Post-Marketing Requirements
• 11.3 Europe (EMA)
  • 11.3.1 Centralized Approval Process
  • 11.3.2 Pharmacovigilance Requirements
• 11.4 Japan (PMDA)
  • 11.4.1 Approval Framework
  • 11.4.2 Safety Monitoring Requirements
• 11.5 India (CDSCO)
  • 11.5.1 Regulatory Approval Pathway
  • 11.5.2 Clinical Trial Requirements
• 11.6 China (NMPA)
  • 11.6.1 Drug Registration Framework
  • 11.6.2 Accelerated Review Programs
• 11.7 Health Technology Assessment Landscape
• 11.8 Reimbursement Policy Trends
• 11.9 Market Access Challenges

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Competitive Benchmarking
• 12.3 Product Positioning Analysis
• 12.4 Strategic Initiatives
  • 12.4.1 Collaborations and Partnerships
  • 12.4.2 Licensing Agreements
  • 12.4.3 Mergers and Acquisitions
  • 12.4.4 Clinical Development Strategies
• 12.5 SWOT Analysis
• 12.6 Future Competitive Outlook

13. Company Profiles

• 13.1 Genentech
  • 13.1.1 Company Overview
  • 13.1.2 Stroke-Relevant Approved Products
  • 13.1.3 Key Indications
  • 13.1.4 Verified Clinical Pipeline
  • 13.1.5 Strategic Outlook
• 13.2 Boehringer Ingelheim
  • 13.2.1 Company Overview
  • 13.2.2 Stroke-Relevant Approved Products
  • 13.2.3 Key Indications
  • 13.2.4 Verified Clinical Pipeline
  • 13.2.5 Strategic Outlook
• 13.3 F. Hoffmann-La Roche Ltd
  • 13.3.1 Company Overview
  • 13.3.2 Stroke-Relevant Approved Products
  • 13.3.3 Key Indications
  • 13.3.4 Verified Clinical Pipeline
  • 13.3.5 Strategic Outlook
• 13.4 Novartis AG
  • 13.4.1 Company Overview
  • 13.4.2 Stroke-Relevant Approved Products
  • 13.4.3 Key Indications
  • 13.4.4 Verified Clinical Pipeline
  • 13.4.5 Strategic Outlook
• 13.5 Bayer AG
  • 13.5.1 Company Overview
  • 13.5.2 Stroke-Relevant Approved Products
  • 13.5.3 Key Indications
  • 13.5.4 Verified Clinical Pipeline
  • 13.5.5 Strategic Outlook
• 13.6 Johnson & Johnson
  • 13.6.1 Company Overview
  • 13.6.2 Stroke-Relevant Approved Products
  • 13.6.3 Key Indications
  • 13.6.4 Verified Clinical Pipeline
  • 13.6.5 Strategic Outlook
• 13.7 Daiichi Sankyo
  • 13.7.1 Company Overview
  • 13.7.2 Stroke-Relevant Approved Products
  • 13.7.3 Key Indications
  • 13.7.4 Verified Clinical Pipeline
  • 13.7.5 Strategic Outlook
• 13.8 Sanofi
  • 13.8.1 Company Overview
  • 13.8.2 Stroke-Relevant Approved Products
  • 13.8.3 Key Indications
  • 13.8.4 Verified Clinical Pipeline
  • 13.8.5 Strategic Outlook
• 13.9 Novo Nordisk
  • 13.9.1 Company Overview
  • 13.9.2 Stroke-Relevant Approved Products
  • 13.9.3 Key Indications
  • 13.9.4 Verified Clinical Pipeline
  • 13.9.5 Strategic Outlook
• 13.10 AstraZeneca PLC
  • 13.10.1 Company Overview
  • 13.10.2 Stroke-Relevant Approved Products
  • 13.10.3 Key Indications
  • 13.10.4 Verified Clinical Pipeline
  • 13.10.5 Strategic Outlook
• 13.11 Merck & Co., Inc.
  • 13.11.1 Company Overview
  • 13.11.2 Stroke-Relevant Approved Products
  • 13.11.3 Key Indications
  • 13.11.4 Verified Clinical Pipeline
  • 13.11.5 Strategic Outlook
• 13.12 GlaxoSmithKline plc
  • 13.12.1 Company Overview
  • 13.12.2 Stroke-Relevant Approved Products
  • 13.12.3 Key Indications
  • 13.12.4 Verified Clinical Pipeline
  • 13.12.5 Strategic Outlook
• 13.13 Eli Lilly and Company
  • 13.13.1 Company Overview
  • 13.13.2 Stroke-Relevant Approved Products
  • 13.13.3 Key Indications
  • 13.13.4 Verified Clinical Pipeline
  • 13.13.5 Strategic Outlook
• 13.14 AbbVie Inc.
  • 13.14.1 Company Overview
  • 13.14.2 Stroke-Relevant Approved Products
  • 13.14.3 Key Indications
  • 13.14.4 Verified Clinical Pipeline
  • 13.14.5 Strategic Outlook

14. Future Outlook

• 14.1 Future Market Projections
• 14.2 Emerging Therapeutic Trends
• 14.3 Next-Generation Stroke Therapies
• 14.4 Precision Medicine Potential
• 14.5 AI and Digital Health Impact
• 14.6 Investment Opportunities
• 14.7 Strategic Recommendations
• 14.8 Analyst Conclusions

15. Methodology

• 15.1 Research Scope
• 15.2 Market Definition
• 15.3 Study Assumptions
• 15.4 Secondary Research Methodology
• 15.5 Primary Research Methodology
• 15.6 Epidemiology Modeling Framework
• 15.7 Market Estimation Methodology
• 15.8 Forecasting Methodology
• 15.9 Data Triangulation
• 15.10 Quality Control and Validation
• 15.11 Abbreviations
• 15.12 References and Data Sources